By admin 
The Treasury Department is currently in the final stages of drafting highly anticipated rules regarding U.S. outbound investment into China’s technology and healthcare sectors. According to recent reports, the Biden-era frameworks, now being refined under the current administration, appear to be trending toward a more permissive stance for pharmaceutical licensing deals than many industry hawks had anticipated. This development is particularly significant given the broader push to "de-risk" the U.S. economy from Chinese influence. While other high-tech sectors like semiconductors, quantum computing, and artificial intelligence have faced draconian restrictions under new national security legislation, the pharmaceutical industry may receive a crucial carve-out.
The proposed rules are expected to allow U.S.-based drugmakers to continue investing in and licensing promising new therapies developed by Chinese biotech firms, provided those assets are not linked to "dual-use" technologies. Specifically, the Treasury Department is looking to prohibit investments related to pathogens or biotechnology that could be weaponized or used for military purposes. However, the vast majority of oncology, immunology, and rare disease treatments—which represent the bulk of current cross-border licensing activity—would likely remain eligible for investment. This nuance is vital for the U.S. pharmaceutical ecosystem; over the past five years, China has become one of the most prolific sources of early-stage drug candidates. American companies often rely on these licensing deals to fill their pipelines, paying upfront fees and milestone payments to Chinese innovators in exchange for the rights to commercialize these drugs in Western markets.
If the Treasury Department moves forward with this relatively lenient approach, it will represent a departure from the more aggressive decoupling strategies sought by some members of Congress. Lawmakers have expressed concerns that any U.S. capital flowing into Chinese biotech firms indirectly strengthens the Chinese Communist Party’s "Made in China 2025" goals. Yet, industry trade groups have argued persuasively that a total ban on licensing would stifle innovation and prevent American patients from accessing potentially life-saving treatments that happen to be discovered in Shanghai or Suzhou. The challenge for the administration remains one of "small yard, high fence"—protecting the most sensitive technologies while allowing the global engine of medical progress to continue turning.
However, even as the U.S. seeks to secure its supply chains and intellectual property from foreign adversaries, it is facing a mounting crisis of accountability at home. An exhaustive analysis of FDA data, highlighted by KFF Health News, has cast a harsh light on the agency’s "post-market" oversight. When the FDA grants approval to a drug—particularly through "accelerated" pathways designed to get treatments to patients faster—it often does so on the condition that the manufacturer conducts further studies to confirm the drug’s safety and efficacy. These are known as Postmarketing Requirements (PMRs) or Postmarketing Commitments (PMCs).
The findings of the analysis are sobering. Hundreds of these post-market studies are currently listed as "delayed," with some lingering in regulatory limbo for more than a decade. In the most egregious cases, manufacturers have yet to even finalize a protocol or a "plan" for the study, years after their product has been generating billions of dollars in revenue from patients and taxpayers. This backlog represents a fundamental breakdown in the regulatory "social contract." The accelerated approval process was designed as a trade-off: the public accepts a higher degree of uncertainty in exchange for earlier access to a drug, with the understanding that the uncertainty will be resolved quickly through rigorous follow-up research.
When these studies are delayed, the consequences are multifaceted. First and foremost is the risk to patient safety. Without confirmatory data, patients may be taking medications that offer no clinical benefit or, worse, cause unforeseen long-term harm. Second, there is the staggering financial cost. Whether the bill is paid by individual patients, private insurance companies, or government programs like Medicare and Medicaid, billions of dollars are being spent on products whose clinical value remains unproven. In essence, the current system allows pharmaceutical companies to be rewarded for products that may ultimately be useless or risky, all while they avoid the expense and scrutiny of the very trials they promised to conduct.
The KFF report notes that while the FDA has the authority to fine companies or even withdraw drugs from the market for failing to complete post-market studies, it rarely exercises these "nuclear options." This perceived leniency has led to a culture of non-compliance among some manufacturers. While major players like Amgen and others have pointed to the complexities of patient recruitment and trial design as reasons for delays, critics argue that these are often convenient excuses for prioritizing new product launches over the boring, expensive work of confirming the safety of existing ones.
This regulatory bottleneck is occurring at a time when the FDA is under more pressure than ever to speed up approvals. The 21st Century Cures Act and subsequent iterations of the Prescription Drug User Fee Act (PDUFA) have provided the agency with more resources, but they have also tilted the scales toward speed. The "Food and Drug Omnibus Reform Act" (FDORA), passed in late 2022, gave the FDA more "teeth" to demand that confirmatory trials be underway at the time of accelerated approval, but the legacy backlog of older drugs remains a persistent problem.
As we look toward the coming week, the intersection of these two stories—the geopolitical balancing act with China and the domestic struggle for drug safety accountability—paints a picture of an industry in flux. On one hand, the U.S. government recognizes that isolationism in biotechnology could harm public health by cutting off access to global innovation. On the other hand, the failure to hold companies accountable for post-approval safety studies suggests a domestic regulatory system that is struggling to keep pace with the industry it oversees.
The pharmaceutical sector remains a crown jewel of the American economy, but its continued success depends on trust. Trust that the medicines being imported or licensed from abroad do not compromise national security, and trust that the drugs on pharmacy shelves have been proven safe and effective through the rigorous application of science. As the Treasury Department finalizes its rules and the FDA grapples with its backlog, the stakes could not be higher for the millions of people who rely on these treatments.
So, as the "jalopies" head toward the orchards this weekend and the "ancient rituals" are observed, the industry would do well to reflect on these challenges. Innovation is a global endeavor, but safety is a local responsibility. The coming months will determine whether the U.S. can successfully navigate the thin line between encouraging international collaboration and enforcing the strict regulatory standards that have long been the hallmark of American medicine. For now, the rotation of the listening party may provide a brief respite from these weighty concerns, but by Tuesday, the industry must return to the task of answering these difficult questions. The health of the nation, and the integrity of the market, depends on it.
